STOCK TITAN

Candel Therapeutics (CADL) Stock News, Nov 2021-Mar 2022

CADL NASDAQ

Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.

Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.

Rhea-AI Summary

Candel Therapeutics (CADL) reported a strong cash position of $82.6 million as of December 31, 2021, up from $35.1 million in 2020, bolstered by a successful IPO. Despite a net loss of $36.1 million for the year, the company plans to present key clinical trial data in 2022, seeking to advance its oncolytic viral immunotherapies for various cancers. Operating expenses increased to $25.9 million, driven by R&D and administrative costs linked to its growth strategy. Candel is positioned for critical milestones with upcoming data readouts expected in mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
-
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) has appointed Dr. Seshu Tyagarajan as the Chief Technical and Development Officer. Tyagarajan brings over 20 years of experience from Novartis, where she led CGT manufacturing strategies, including the BLA submission for Kymriah, the first FDA-approved CAR-T therapy. Her expertise in biologics manufacturing is expected to enhance Candel’s development efforts for oncolytic viral immunotherapy, which targets solid tumors. The company aims to leverage her insights to elevate its technical operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
management
-
Rhea-AI Summary

Candel Therapeutics, Inc. (Nasdaq: CADL) has secured a $25 million loan from Silicon Valley Bank, with $20 million available immediately and up to $5 million contingent on specific milestones. This financing extends the company's cash runway into Q4 2023, providing operational flexibility ahead of key clinical trials, including CAN-2409 and CAN-3110. CEO Paul Peter Tak highlights the attractive, non-dilutive terms of the loan as beneficial for upcoming data release and trial initiation, crucial for the company's oncolytic viral immunotherapy programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
Rhea-AI Summary

Candel Therapeutics, Inc. (Nasdaq: CADL) has appointed Francesca Barone, M.D., Ph.D., as its new Chief Scientific Officer. With over 20 years of expertise in immunology and drug development, Dr. Barone previously served as Candel's Vice President, Head of Research. She has substantial experience from her roles at Kintai Therapeutics and Senda Biosciences. Dr. Barone expressed optimism about the company's investigational immunotherapies aimed at treating cancer, emphasizing their unique ability to induce strong immune responses. This leadership change aims to enhance Candel's clinical development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
management
-
Rhea-AI Summary

Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company specializing in oncolytic viral immunotherapies, announced upcoming presentations at two virtual investor conferences in January 2022. Paul Peter Tak, CEO, will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, with on-demand viewing starting at 7:00 am ET. He will also present live at the B. Riley Securities’ 2022 Oncology Conference on January 28, 2022, at 11:30 am ET. The company focuses on advancing cancer treatments through innovative engineered viruses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
conferences
-
Rhea-AI Summary

Bionaut Labs and Candel Therapeutics have formed a strategic collaboration to advance preclinical development of remote-controlled microscale robots for targeted delivery of oncolytic viral immunotherapies to brain tumors. Utilizing Bionaut’s precision medicine technology, the partnership aims to enhance therapeutic efficacy for high-grade glioma patients. Both companies will retain rights to their platforms while working together towards clinical trials. Terms of the agreement remain undisclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) announced a collaboration with the Partnership for Accelerating Cancer Therapies (PACT) for a biomarker analysis in a phase 2 clinical trial targeting non-small cell lung cancer (NSCLC). The study will evaluate the efficacy of CAN-2409 combined with immune checkpoint inhibitors following inadequate responses to initial treatments. With three patient cohorts, the collaboration aims to identify early biological indicators of treatment response. This partnership enhances Candel's research credibility and aims to advance therapeutic options for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
partnership
-
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) presented encouraging data from its phase 1 trial of CAN-3110 at the SITC Annual Meeting. This oncolytic virus therapy showed significant T-cell infiltration and immune activation in patients with recurrent high-grade glioma. Preliminary data previously reported at ASCO indicated an overall survival of 11.7 months. The histological analysis confirmed persistence of viral antigens and a strong immune response, suggesting the potential of CAN-3110 to improve treatment outcomes for patients with this challenging cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) reported its Q3 financial results, announcing a net loss of $16.2 million for the quarter, a substantial increase from $2.6 million in Q3 2020. Cash reserves as of September 30, 2021, stood at $88.4 million, bolstered by an IPO in August 2021. Research and development expenses surged to $5.3 million from $1.8 million year-over-year, attributed to increased clinical trial activities. The company remains on track to fund operations into Q2 2023, with several clinical presentations highlighting advancements in its oncolytic viral therapies, CAN-2409 and CAN-3110.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
Rhea-AI Summary

On November 2, 2021, Candel Therapeutics, Inc. (Nasdaq: CADL) announced that CEO Paul Peter Tak will speak at several investor conferences in November.

  • Credit Suisse 30th Annual Healthcare Conference: Fireside Chat on November 8, 2021, at 11:20 am ET.
  • BMO Biopharma Spotlight Series: Panel Discussion on November 8, 2021, at 12:45 pm ET.
  • Jefferies London Healthcare Conference: Fireside Chat on November 17, 2021, at 1:00 pm GMT.

For more information and webcasts, visit Candel's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.10%
Tags
conferences

FAQ

What is the current stock price of Candel Therapeutics (CADL)?

Candel Therapeutics (CADL) last closed at $5.04.

What is the market cap of Candel Therapeutics (CADL)?

The market cap of Candel Therapeutics (CADL) is approximately $395.4M.